Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Jacqueline V. Aredo et al. published in JTO Clinical and Research Reports:
“Report, JTO Clinical and Research Reports, on DLL3 expression in EGFR NSCLC after SCLC transformation. DLL3 positive in 11/12 patients. Two of these patients received tarlatamab (one with osimertinib) with clinical benefit. Need prospective data here!”
Title: Brief Report: DLL3 Immunohistochemical Expression in Neuroendocrine Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy
Authors: Jacqueline V. Aredo, Surbhi Singhal, Gerald J. Berry, Farshad Moradi, Heather A. Wakelee, Nathaniel J. Myall, Kavitha J. Ramchandran, Millie Das, Carlos J. Suarez, Joel W. Neal, and Jonathan W. Riess
You can read the Full Article in JTO Clinical and Research Reports.
More posts featuring Stephen V Liu.